Two Years After Winning Accelerated Approval, GSK Pulls Blenrep At FDA’s Request

Two years after its blood cancer treatment Blenrep (belantamab mafodotin) won accelerated approval from the FDA, GSK has removed the drug from the market in the U.S. at the FDA’s request.
Source: Drug Industry Daily